BYSI BeyondSpring Inc.

18.2
+0.6  (+3%)
Previous Close 17.6
Open 18
Price To Book 21.16
Market Cap 421781305
Shares 23,174,797
Volume 703
Short Ratio
Av. Daily Volume 7,627

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met primary endpoint of non-inferiority vs Neulasta. NDA filing due 2H 2019.
Plinabulin (Trial 105)
Chemotherapy-induced neutropenia (CIN)
Phase 3 interim data due early 2019.
Plinabulin (Trial 103)
Non small cell lung cancer - refractory
Phase 2 top-line positive data released October 23, 2018. Final data due 1H 2019.
Plinabulin + TAC (Trial 106)
Chemotherapy-induced neutropenia (CIN)
Phase 1/2 initiation announced October 4, 2018.
Plinabulin + Opdivo +Yervoy
Small-cell lung cancer (SCLC)